Skip to main content
Premium Trial:

Request an Annual Quote

RXi Technology Shows Potential as miRNA Mimic In Vitro

Premium

RXi Pharmaceuticals said this week that, in collaboration with Miragen Therapeutics, it has generated positive in vitro data demonstrating the use of its self-delivering RNAi agents to enhance the activity of a particular microRNA.

Specifically, the companies used the self-delivering molecules to create an miRNA mimic capable of down-regulating a reporter gene whose expression is controlled by the microRNA in cell culture model systems developed by Miragen.

According to Miragen President and CEO Bill Marshall, miRNA therapeutics "that mimic native sequences require special approaches for delivery. We are excited that RXi's self-delivering technology demonstrates this compatibility with microRNA sequences from our portfolio."

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.